March 8, 2011 – Nile Therapeutics is pursuing a new indication for cenderitide, formerly CD-NP. The company is looking to develop the drug as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from the hospital.

March 8, 2011 – A third-generation bare-metal stent system has received the CE Mark in Europe. Boston Scientific’s Omega platinum chromium coronary stent system is intended to provide interventional cardiologists with improved acute performance in treating patients with coronary artery disease.

March 8, 2011 – The U.S. Food and Drug Administration (FDA) announced monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), made by Gilead Sciences. Ambrisentan is used to treat pulmonary arterial hypertension (PAH).

March 7, 2011 – Massachusetts General Hospital (MGH) has granted an exclusive license to Santaris Pharma A/S for intellectual property related to the regulation of microRNA for the treatment of cardiovascular disorders.

March 7, 2011 – Nile Therapeutics will partner with Medtronic to develop natriuretic peptide, cenderitide, formerly CD-NP, for heart failure and renal disease applications.

March 7, 2011 – A new digital intra-vascular ultrasound (IVUS) catheter has been cleared in Japan. The Eagle Eye Platinum digital IVUS catheter, from Volcano, was introduced at the Percutaneous Coronary Intervention (PCI) Live Demonstration Course in Kurashiki.

March 7, 2011 – Each year between 100,000 and 180,000 Americans die as the result of pulmonary embolism, a complication from blood clots in the lungs. The Vascular Disease Foundation urges Americans, especially women, to learn about the risks of venous blood clots to help prevent these deaths.

March 7, 2011 – Last week Medtronic Inc. cancelled its five contracts with Novation LLC, one of the largest U.S. group purchasing organizations (GPOs), which previously represented $2 billion. The contracts included reduced price, large group purchases of cardiovascular and orthopedic devices.

March 7, 2011 – A pilot study testing a system designed to improve acute coronary syndrome (ACS) revascularization has been successfully completed. The study looked at the Picso Impulse System, from Miraco Medical, which is used following primary percutaneous coronary intervention (PCI) to diminish ischemia.

March 4, 2011 - Occlutech GmbH received a favorable court ruling in Stockholm, Sweden in the ongoing patent litigation case with AGA Medical-St. Jude Medical.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now